Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
What GLP-1 Patent Estates Can Learn from the Sofosbuvir Litigation History The GLP-1 class semaglutide (Novo Nordisk), tirzepatide (Eli Lilly), retatrutide (Eli Lilly, Phase III), orforglipron (Eli Lilly) is generating patent portfolios that structurally resemble the sofosbuvir estate, with base compound patents surrounded by secondary filings on formulations, dosing devices, combination regimens, and cardiovascular or renal outcome indications supported by post-approval trial data
Regular follow-up appointments will be scheduled to ensure the medication is effective and well-tolerated
Am J Physiol Endocrinol Metab 299: E1076-1086, 2010
Diaz-Vivancos P, de Simone A, Kiddle G, Foyer CH
US$ 26.66
US$ 29.89
US$ 24.77
US$ 20.04
